Drug intelligence / Profile preview

vopikitug

Development stage
Preclinical
Lead developer
Roche
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

**Vopikitug (RG6292, RO7296682)** is an afucosylated human IgG1 monoclonal antibody developed by Roche that targets **CD25 (IL-2 receptor alpha subunit)** on regulatory T cells (Tregs). Engineered to selectively deplete Tregs via enhanced antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis while preserving IL-2 signaling on effector T cells, it aims to enhance antitumor immunity without broad immunosuppression. Administered intravenously, it demonstrated dose-dependent peripheral and intratumoral Treg depletion in phase 1 trials for advanced solid tumors, both as monotherapy and in combination with atezolizumab, but showed insufficient clinical efficacy leading to trial terminations. Preclinical data also supported potential in acute myeloid leukemia (AML), particularly in CD25-expressing leukemic stem cells.

Other names
vopikitug
02

Targets

IL2RA (Interleukin-2 receptor alpha subunit)

Beyond the preview

Go deeper on vopikitug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on vopikitug.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call